期刊文献+

反应停对增生性瘢痕细胞超微结构的影响 被引量:2

Thalidomide inhibits formation of hypertrophic scar
下载PDF
导出
摘要 目的 为探讨血管形成抑制剂反应停对增生性瘢痕的治疗机制提供形态学依据 .方法 通过建立兔耳增生性瘢痕模型 ,观察血管形成抑制剂反应停对增生性瘢痕超微结构的影响 .结果 血管形成抑制剂反应停作用后增生性瘢痕组织中的毛细血管基膜不完整 ,内皮细胞变性 ,血管形成过程受损 ,成纤维细胞发生变性 ,内质网等细胞器减少 ,细胞外基质也相应减少 .结论 反应停可能是通过影响血管形成而致增生性瘢痕组织中的成纤维细胞变性 .因而血管抑制剂可抑制瘢痕增生 . AIM To investigate the mechanism of the effect of thalidomide on hypertrophic scar. METHODS By establishing rabbit hypertrophic scar model, we observed the effect of thalidomide on the ultrastructure of hypertrophic scar. RESULTS Treated with angiogenesis inhibitor thalidomide, the basement membrane of capillary became unintegrated, the endothelial cells degenerated, and the procedure of angio genesis was damaged. The fibroblasts of hypertrophic sar became degenerated, the endoplasmic reticulum small and reduced, and the extra cellular matrix also reduced. CONCLUSION The degeneration of hypertrophic scar fibroblasts and endothelial cells may be caused by the inhibitory effect of thalidomide on angiogenesis. So the angiogenesis inhibitor can inhibit the formation of hypertrophic scar.
出处 《第四军医大学学报》 北大核心 2002年第9期810-812,共3页 Journal of the Fourth Military Medical University
关键词 血管形成抑制剂 成纤维细胞 内皮细胞 超微结构 瘢痕 angiogenesis inhibitor fibroblast endothelial cell ultrastructure scar
  • 相关文献

参考文献2

二级参考文献7

  • 1Morris D E,Plast Reconstr Surg,1997年,100卷,3期,674页
  • 2Debus E S,Zentralbl Chir,2000年,125卷,suppl 1期,49页
  • 3Deng Z H,第四军医大学学报,1999年,19卷,1期,70页
  • 4Yan R L,第四军医大学学报,1999年,20卷,4期,291页
  • 5Majno G,Am J Pathol,1998年,153卷,4期,1035页
  • 6Su C W,Clin Plast Surg,1998年,25卷,3期,451页
  • 7Polo M,J Burn Care Rehabil,1997年,18卷,3期,477页

共引文献112

同被引文献29

  • 1李西平,刘叙仪,王洁,王曾礼,蒋薇,张毅,刘元林.反应停对人肺腺癌亲代及耐顺铂细胞系碱性成纤维细胞生长因子表达影响[J].中国呼吸与危重监护杂志,2003,2(1):40-43. 被引量:3
  • 2顾有守,吴铁强.沙利度胺及其在皮肤科的应用(一)[J].岭南皮肤性病科杂志,2005,12(3):273-275. 被引量:4
  • 3顾有守,吴铁强.沙利度胺及其在皮肤科的应用(二)[J].岭南皮肤性病科杂志,2005,12(4):348-350. 被引量:4
  • 4李邻峰.皮炎湿疹类皮肤病诊疗进展[J].继续医学教育,2006,20(23):28-32. 被引量:4
  • 5McCredie J,Willert HG. Longitudinal limb deficiencies and the sclerotomes.potential uses and limitations.An analysis of 378 dysmelic malformations induced by thalidomide.J Bone Joint Surg Br, 1999,81:9~23
  • 6Corral LG.Kaplan G,Immunomodulation by Thalidomide and Thalidomide analogues.Ann Rheum Dis,1999,58(Suppl 1): 1107~1113
  • 7Haslett PA, Corral LG, Albert M, et al.Thalidomide costimulates primary human T lymphocytes,preferentially inducing proliferation,cytokine production,and cytotosic responses the CD8+subset.J ExpMed, 1998,187:1885~1892
  • 8kruse FE ,Joussen AM ,Rohrschneider K,et al. Thalidomide inhibits corneal angiogenesis induced by vascular endotelial growth factor[J].Graefes arch Clin Exp0phslmol, 1998,236(6):461~466
  • 9Stephens TD,Bunde CJ,Fillmore BJ.Mdchanidm of action in Thalidomide teratogenesis. Biochem Pharmacol, 2000,59:1489~1499
  • 10Parman T,Wiley MJ,Wells PG.Free tadical-mediated oxidative DNA damage in the mechanism of Thalidomide teratogenicity. Nat Med, 1999,(5):582~585

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部